- pause slideshow
Some researchers argue that slowing the rate of biological ageing could be the best way to delay development of chronic diseases, such as cardiovascular disease, cancer and arthritis.
There are >185 million people with hepatitis C infection worldwide but new treatments mean that most people with access to therapy can now be cured.
The board set up to review medicines legislation and to advise UK government ministers on pharmacy policy is due to make recommendations on how the rules around ‘supervision’ should change.
Evidence is emerging that biologically active compounds in foods could play an important role in the development of disease.
The British Medical Association has lambasted the decision by the government to impose a new contract on junior doctors working in the NHS.
Electronic repeat dispensing service at heart of PSNC’s proposals for clinically focused pharmacy serviceSubscription
An electronic repeat dispensing service for people with long-term conditions should become routine for community pharmacists in England, according to proposals for a more clinically led profession drawn up by national negotiators.
A credit card-sized patient information card that pharmacists can give to female patients to warn them about the risks of taking valproate while pregnant has been produced by the Medicines and Healthcare products Regulatory Agency.
NHS trusts should deploy more clinical pharmacists, including pharmacist prescribers, and use them to drive value from the £6.7bn that NHS hospitals spends on medicines every year, Lord Carter has advised in his final review of English NHS acute hospitals.
Contaminated packs of St John’s Wort herbal medicines are being recalled because they contain higher than recommended levels of a toxic pyrrolizidine alkaloid, which can cause liver problems in patients.
Ongoing mutations of influenza virus surface proteins mean a different flu vaccine must be used each year, but researchers think they may have found a novel antiviral drug that could protect against a variety of influenza strains.
The UK’s self-regulatory system for detecting and sanctioning pharmaceutical companies which break marketing regulations by promoting drugs off-label should be reformed, according to research.
The validity of the data produced by a pivotal trial to gain approval for the direct oral anticoagulant, rivaroxaban (Xarelto), from the US and European regulators, has been called into question by an investigation.
Analysis of more than 185,000 young people taking antipsychotics reveals exposure time and olanzapine use as risk factors for diabetes.
Study of more than 50,000 children shows prenatal exposure to paracetamol associated with 13% increased risk of asthma.
Placebo administration induced clinical and neuronal responses in Parkinson’s patients taking apomorphine.
Patients had significantly better adherence scores following community pharmacy intervention measures.
Methods for small scale, point-of-use manufacture of drugs have now reached an advanced stage, delegates heard at the American Society of Health-System Pharmacists ‘midyear clinical meeting’ in New Orleans, Louisiana.
“Talk to your local MP and invite them to your pharmacy!” This was the advice given by Oliver Colvile, vice chair of the All-Party Pharmacy Group (APPG), at an evening of discussion hosted by the Royal Pharmaceutical Society (RPS) London Central Local Practice Forum at Portcullis House on 6 January 2016.
Moving closer to a paperless NHSSubscription
The Pharmacy Informatics Forum highlighted the speed at which electronic prescribing is growing within UK hospitals and how health professionals should approach the changes to get the best results.
Cyramza indication extendedSubscription
The indication of Cyramza (ramucirumab; Eli Lilly), in combination with FOLFIRI (irinotecan, folinic acid, and 5‑fluorouracil), has been extended to include the treatment of adult patients with metastatic colorectal cancer with disease progression on or after prior therapy with bevacizumab, oxaliplatin and a fluoropyrimidine. In addition, Cyramza in combination with docetaxel is also indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung ...
Revolade for idiopathic ITPSubscription
The indication of Revolade (eltrombopag; Novartis) has been extended to include adult chronic immune (idiopathic) thrombocytopenic purpura (ITP) patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).
Desmopressin patient safety alertSubscription
A patient safety alert has been issued by NHS England to raise awareness of the risk of severe dehydration and death caused by an omission or delay of desmopressin in patients with cranial diabetes insipidus. Following reports of patient safety incidents caused by an omission or delay in the provision of desmopressin, providers of NHS care are asked to consider if immediate action needs to be taken locally to raise awareness and reduce the risk of these incidents from occurring. The
NICE recommends nintedanibSubscription
The National Insitute for Health and Care Excellence (NICE) has recommended nintedanib as an option for treating idiopathic pulmonary fibrosis if the person has between 50% and 80% of their predicted forced vital capacity (FVC); the company provides nintedanib with the discount agreed in the patient access scheme; and treatment is stopped if disease progresses (a confirmed decline in percent predicted FVC of 10% or more) in any 12‑month period. Further details can be found on the
NICE does not recommend ramucirumabSubscription
The National Institute for Health and Care Excellence (NICE) has not recommended ramucirumab alone or with paclitaxel for advanced gastric cancer or gastro-oesophageal junction adenocarcinoma previously treated with chemotherapy. However, people whose treatment with ramucirumab was started before this guidance was published should be able to continue treatment until they and their clinician consider it appropriate to stop. Further details can be found on the
NICE recommends panobinostatSubscription
The National Institute for Health and Care Excellence (NICE) has recommended panobinostat in combination with bortezomib and dexamethasone, within its marketing authorisation, as an option for treating multiple myeloma, that is, for “adult patients with relapsed and/or refractory multiple myeloma who have received at least two prior regimens including bortezomib and an immunomodulatory agent” when the company provides panobinostat with the discount agreed in the patient access scheme. ...
NICE recommends prostate cancer drugsSubscription
The National Institute for Health and Care Excellence (NICE) has recommended Radium‑223 dichloride as an option for treating adults with hormone‑relapsed prostate cancer, symptomatic bone metastases and no known visceral metastases, if they have had treatment with docetaxel and the company ...
NICE recommends olaparibSubscription
The National Institute for Health and Care Excellence (NICE) has recommended olaparib within its marketing authorisation as an option for treating adults with relapsed, platinum sensitive ovarian, fallopian tube or peritoneal cancer who have BRCA1 or BRCA2 mutations and whose disease has responded to platinum based chemotherapy if they have had three or more courses of platinum based chemotherapy and the drug cost of olaparib for people who remain on treatment after 15 months will be ...